NASDAQ : VYNE

VYNE Therapeutics Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 28.56 USD (At close: Jul 27, 2026) · Market cap 19.05M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

As of July 27, 2026, VYNE Therapeutics Inc. was acquired by Yarrow Bioscience, Inc., in a reverse merger transaction. VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company’s lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.

Details

NameVYNE Therapeutics Inc.
SectorHealthcare
IndustryBiotechnology
Employees10
Founded2003
Ipo Date2018-01-25
CeoDavid Domzalski
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS92941V4077
Cusip92941V407
Cik1566044
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
David T. DomzalskiChief Executive Officer, President and Director
Dr. Iain A. Stuart Ph.D.Chief Scientific Officer
Mutya Harsch J.D.General Counsel, Chief Legal Officer and Company Secretary
Tyler Zeronda CPAChief Financial Officer and Treasurer
Dr. Darrell S. Rigel FAAD, M.D.Consultant

Contact

AddressP.O. BOX 125, Stewartsville, New Jersey 08886, United States
Phone800 775 7936
Websitehttps://vynetherapeutics.com